Biofrontera Net Income
| BFRI Stock | USD 0.82 0.02 2.38% |
As of the 8th of February, Biofrontera shows the Mean Deviation of 3.74, standard deviation of 6.27, and Risk Adjusted Performance of (0.02). Biofrontera technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Biofrontera Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.3061 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -16 M | -16.8 M | |
| Net Loss | -736 K | -772.8 K | |
| Net Loss | -16 M | -16.8 M | |
| Net Loss | (2.90) | (3.04) | |
| Net Income Per E B T | 0.90 | 0.81 |
Biofrontera | Net Income | Build AI portfolio with Biofrontera Stock |
The Net Income trend for Biofrontera offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Biofrontera is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Biofrontera's Net Income Growth Pattern
Below is the plot of the Net Income of Biofrontera over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Biofrontera financial statement analysis. It represents the amount of money remaining after all of Biofrontera operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Biofrontera's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Biofrontera's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (17.76 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Biofrontera Net Income Regression Statistics
| Arithmetic Mean | (13,518,550) | |
| Coefficient Of Variation | (55.49) | |
| Mean Deviation | 4,797,130 | |
| Median | (10,982,000) | |
| Standard Deviation | 7,501,707 | |
| Sample Variance | 56.3T | |
| Range | 37.1M | |
| R-Value | (0.34) | |
| Mean Square Error | 53T | |
| R-Squared | 0.12 | |
| Significance | 0.18 | |
| Slope | (506,499) | |
| Total Sum of Squares | 900.4T |
Biofrontera Net Income History
Other Fundumenentals of Biofrontera
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Biofrontera Net Income component correlations
Biofrontera Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Biofrontera is extremely important. It helps to project a fair market value of Biofrontera Stock properly, considering its historical fundamentals such as Net Income. Since Biofrontera's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Biofrontera's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Biofrontera's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value - what Biofrontera's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Biofrontera 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Biofrontera's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Biofrontera.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Biofrontera on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Biofrontera or generate 0.0% return on investment in Biofrontera over 90 days. Biofrontera is related to or competes with Gelteq Limited, ProPhase Labs, Aytu BioScience, Evogene, Dogwood Therapeutics, Sensei Biotherapeutics, and Trinity Biotech. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treat... More
Biofrontera Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Biofrontera's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Biofrontera upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.06) | |||
| Maximum Drawdown | 34.13 | |||
| Value At Risk | (7.59) | |||
| Potential Upside | 6.76 |
Biofrontera Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biofrontera's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Biofrontera's standard deviation. In reality, there are many statistical measures that can use Biofrontera historical prices to predict the future Biofrontera's volatility.| Risk Adjusted Performance | (0.02) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.11) |
Biofrontera February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.1) | |||
| Mean Deviation | 3.74 | |||
| Coefficient Of Variation | (2,436) | |||
| Standard Deviation | 6.27 | |||
| Variance | 39.37 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.47) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.11) | |||
| Maximum Drawdown | 34.13 | |||
| Value At Risk | (7.59) | |||
| Potential Upside | 6.76 | |||
| Skewness | 1.43 | |||
| Kurtosis | 8.26 |
Biofrontera Backtested Returns
Biofrontera secures Sharpe Ratio (or Efficiency) of -0.0317, which signifies that the company had a -0.0317 % return per unit of risk over the last 3 months. Biofrontera exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Biofrontera's Risk Adjusted Performance of (0.02), mean deviation of 3.74, and Standard Deviation of 6.27 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 2.49, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Biofrontera will likely underperform. At this point, Biofrontera has a negative expected return of -0.2%. Please make sure to confirm Biofrontera's value at risk, as well as the relationship between the accumulation distribution and day typical price , to decide if Biofrontera performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.4 |
Poor reverse predictability
Biofrontera has poor reverse predictability. Overlapping area represents the amount of predictability between Biofrontera time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Biofrontera price movement. The serial correlation of -0.4 indicates that just about 40.0% of current Biofrontera price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.4 | |
| Spearman Rank Test | -0.45 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Biofrontera reported net income of (17.76 Million). This is 105.2% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 103.11% higher than that of the company.
Biofrontera Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Biofrontera's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Biofrontera could also be used in its relative valuation, which is a method of valuing Biofrontera by comparing valuation metrics of similar companies.Biofrontera is currently under evaluation in net income category among its peers.
Biofrontera Institutional Holders
Institutional Holdings refers to the ownership stake in Biofrontera that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Biofrontera's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Biofrontera's value.| Shares | Tower Research Capital Llc | 2025-03-31 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Scotia Capital Inc | 2025-03-31 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | Jpmorgan Chase & Co | 2025-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | Two Sigma Securities, Llc | 2025-06-30 | 0.0 | Rosalind Advisors, Inc. | 2025-06-30 | 976.4 K | Aigh Capital Management, Llc | 2025-06-30 | 974.5 K | Geode Capital Management, Llc | 2025-06-30 | 40.4 K |
Biofrontera Fundamentals
| Return On Equity | -11.92 | ||||
| Return On Asset | -0.65 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0.90) % | ||||
| Current Valuation | 11.38 M | ||||
| Shares Outstanding | 11.65 M | ||||
| Shares Owned By Insiders | 12.18 % | ||||
| Shares Owned By Institutions | 25.49 % | ||||
| Number Of Shares Shorted | 251.79 K | ||||
| Price To Book | 0.65 X | ||||
| Price To Sales | 0.26 X | ||||
| Revenue | 37.3 M | ||||
| Gross Profit | 23.94 M | ||||
| EBITDA | (14.44 M) | ||||
| Net Income | (17.76 M) | ||||
| Cash And Equivalents | 31.91 M | ||||
| Cash Per Share | 1.36 X | ||||
| Total Debt | 4.92 M | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | (0.22) X | ||||
| Cash Flow From Operations | (10.27 M) | ||||
| Short Ratio | 0.63 X | ||||
| Earnings Per Share | (1.50) X | ||||
| Target Price | 6.0 | ||||
| Number Of Employees | 92 | ||||
| Beta | 0.63 | ||||
| Market Capitalization | 9.56 M | ||||
| Total Asset | 22.1 M | ||||
| Retained Earnings | (117.41 M) | ||||
| Working Capital | 8.68 M | ||||
| Net Asset | 22.1 M |
About Biofrontera Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Biofrontera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofrontera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is there potential for Biotechnology market expansion? Will Biofrontera introduce new products? Factors like these will boost the valuation of Biofrontera. Projected growth potential of Biofrontera fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.50) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
Understanding Biofrontera requires distinguishing between market price and book value, where the latter reflects Biofrontera's accounting equity. The concept of intrinsic value - what Biofrontera's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push Biofrontera's price substantially above or below its fundamental value.
It's important to distinguish between Biofrontera's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biofrontera should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biofrontera's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.